Blog - Page 1073 of 5712

WednesdayFeb 16, 2022 11:17 am

QualityStocksNewsBreaks – Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF) CEO Featured in Recent Power Play Interview

Eat Well Group (CSE: EWG) (OTC: EWGFF) CEO Marc Aneed was interviewed during a recent Power Play by the Market Herald interview. Interviews for the Power Play by the Market Herald spotlight interviews with company executives about their latest news, and in this case, Power Play host Shoran Devi sat down with Aneed to talk about the company’s recent private placement. During the interview, Aneed explained that Eat Well Group has closed a nonbrokered private placement with Nurture Healthy Food LLP for gross proceeds of more than $5 million. As part of the private placement, Eat Well issued 6,690,666 units…

WednesdayFeb 16, 2022 11:13 am

Following Successful Sildenafil Animal Study, Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Plans for More Studies in 2022

Lexaria’s animal study could be the first step to developing faster and better acting sildenafil oral formulations The most prominent study for Lexaria in 2022 is HYPER-H21-4, investigating patented DehydraTECH(TM)-CBD for hypertension and heart disease Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced positive findings in an animal study that evaluated DehydraTECH(TM) processing of the phosphodiesterase inhibitor (PDE5 inhibitor) sildenafil as potential use for erectile dysfunction management. A clear trend emerged during the course of the study – a faster and higher overall delivery of sildenafil into the bloodstream (https://ibn.fm/oU4wW). During the animal study, it…

TuesdayFeb 15, 2022 3:19 pm

QualityStocksNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) Distinctive with Phased Approach to Novel Therapeutics Development

Mydecine (NEO: MYCO) (OTC: MYCOF), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, was featured in a recent Bell2Bell Podcast episode in which its co-founder, chairman and CEO Josh Bartch shared the company’s goals for the new year. Of note was Mydecine’s phased approach, which entails understanding the imperfections of initial formulations and then improving aspects such as the nature of half-life, controllability delivery time, onset time, anxiety associated with different molecules, etc., in order to make them more effective. This approach has set the company apart from its peers. A…

TuesdayFeb 15, 2022 1:25 pm

QualityStocksNewsBreaks – FuelPositive Corporation (TSX.V: NHHH) (OTCQB: NHHHF) CEO Featured in Latest Stock2Me Podcast Episode

FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF), a Canadian-based, growth-stage company committed to providing commercially viable and sustainable, cradle-to-cradle, clean-energy solutions, has announced that CEO Ian Clifford appears in the most recent episode of the Stock2Me podcast. The podcast comes from InvestorBrandNetwork (“IBN”), a multifaceted communications organization, and interviews individuals who are actively revolutionizing age-old business practices within their respective markets. During the interview, Clifford talked about FuelPositive’s rapid development in 2021 and the first part of 2022 as the company works to change the landscape surrounding ammonia production. Clifford and podcast host Stuart Smith also discussed the company’s focus on sustainability.…

TuesdayFeb 15, 2022 1:19 pm

QualityStocksNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN), The Chopra Foundation Partner to Uncover Potential of Psychedelic Therapies in Mental Health

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” has entered a strategic partnership with The Chopra Foundation, a not-for-profit organization founded by Dr. Deepak Chopra, dedicated to improving health and well-being. Under the collaboration, The Chopra Foundation is working closely with Cybin to support education and awareness about its groundbreaking research to harness the potential of psychedelic therapies in mental health. Emerging research shows the potential for psychedelic-assisted therapy to improve the quality of life for people suffering with mental illnesses, including those specific indications that Cybin is targeting, such as major depressive…

TuesdayFeb 15, 2022 12:46 pm

QualityStocksNewsBreaks – Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF) Closes Strategic Investment, Setting Stage for International Growth, Further Collaboration

Eat Well Investment Group (CSE: EWG) (OTC: EWGFF) today announced that it has closed a strategic investment from Nurture Healthy Food LLP, a wholly owned subsidiary of Nurture Capital LLC, on a non-brokered private placement basis for gross proceeds of $5,017,999.50. Per the strategic investment, the company issued 6,690,666 units, each at a price of $0.75, with each unit comprised of one common share of the company and one half of one common share purchase warrant at an exercise price of $1.00 per share, exercisable for 36 months after closing of the offering. “Our partnerships form an integral component of…

TuesdayFeb 15, 2022 12:31 pm

QualityStocksNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Names BayMedica VP of Sales, Releases Q2 2022 Report

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, has appointed Gerard (Jerry) P. Griffin III as vice president of sales and marketing at BayMedica, a wholly owned subsidiary of InMed. In his new role, Griffin will manage the commercialization of BayMedica’s health and wellness business including existing products as well as the launch of new products. Griffin brings a rich background to this position, having a proven track record as a veteran sales executive. He has served in several senior positions in Fortune 500 companies, including most recently as VP of sales…

TuesdayFeb 15, 2022 11:04 am

QualityStocksNewsBreaks – Kronos Advanced Technologies Inc.’s (KNOS) Patent Pending Graphene Masks Provide Superior Efficacy with 99.9% Viral and Bacterial Filtration

Kronos Advanced Technologies (OTC: KNOS), a revenue-generating product development and production company that has significantly changed the way air is moved, filtered and disinfected, today announced test results from Nelson Labs demonstrating significantly enhanced bacterial filtration efficiency (“BFE”) and viral filtration efficiency (“VFE”). According to the update, Kronos' designed and U.S. manufactured 5-ply graphene face masks remove 99.9% of bacteria and virus particles compared to the common and far less efficacious ASTM level 3 mask. The company believes that, with BFE and VFE levels over 99.9%, these are the highest filtration efficiency numbers for any face masks in the market.…

TuesdayFeb 15, 2022 9:30 am

Identified Psilocybin and MDMA Supplier, New Addition Strengthens Mydecine Innovations Group Inc.’s (NEO: MYCO) (OTC: MYCOF) Board Experience

Biotechnology company Mydecine Innovations Group is devoted to advancing the use of psychedelics for the treatment of mental illnesses and addiction Mydecine has necessary license to provide psilocybin and MDMA under Canada’s SAP program, which allows medical providers to request otherwise unavailable drug substances for the treatment of patients who have not seen success with available treatment options The license allows Mydecine to provide psilocybin and MDMA (Ecstasy) through its licensed Alberta facility and collaboration with non-profit drug development institute Applied Pharmaceutical Innovation The company has named pharmaceutical scientist and entrepreneur Dr. Victoria Hale to its Board of Directors, strengthening…

TuesdayFeb 15, 2022 9:15 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Pushing the Conversation on Psychedelics and Access to Psychedelic Treatments for Persons Living with Mental Health Conditions

Delic seeks to bring mental health treatment closer to the people through an aggressive expansion plan In a study conducted by The Harris Poll on behalf of the company, it was noted that 65% of Americans dealing with mental health conditions believe that psychedelic medicine should be made available Studies such as these are helping Delic drive the conversation on psychedelics forward The company seeks to take this conversation further with its participation at this year’s Emerald Conference Over 51.5 million people have experienced a mental health condition in the United States alone, with the figures rising owing to the…

Site Search

Company Search